Form 8-K

8-K — NEUROONE MEDICAL TECHNOLOGIES Corp

Accession: 0001213900-26-088719

Filed: 2026-08-13

Period: 2026-08-13

CIK: 0001500198

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — ea0301787-8k_neuroone.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED AUGUST 13, 2026 (ea030178701ex99-1.htm)

GRAPHIC (ea030178701_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0301787-8k_neuroone.htm · Sequence: 1

false

0001500198

2026-08-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of Earliest Event Reported): August 13, 2026

NeuroOne

Medical Technologies Corporation

(Exact

name of registrant as specified in its charter)

Delaware

001-40439

27-0863354

(State

or other jurisdiction

incorporation)

(Commission

File Number)

(IRS

Employer

Identification No.)

7599

Anagram Dr., Eden Prairie, MN 55344

(Address

of principal executive offices and zip code)

952-426-1383

(Registrant’s

telephone number including area code)

(Registrant’s

former name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written communications pursuant

to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common Stock, par value

$0.001 per share

NMTC

The Nasdaq Stock Market

LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

Growth Company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02 Results of Operations and Financial Condition.

August 13, 2026, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its

financial results for the third fiscal quarter ended June 30, 2026. A copy of this press release is furnished herewith as

Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by

reference.

accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 of this Current Report, including Exhibit

99.1 hereto, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall

it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange

Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set

forth by specific reference in such a filing.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release, dated August 13, 2026

104

Cover Page Interactive Data File (embedded with Inline

XBRL document).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its

behalf by the undersigned hereunto duly authorized.

NEUROONE

MEDICAL TECHNOLOGIES CORPORATION

Dated: August 13, 2026

By:

/s/ David

Rosa

David Rosa

Chief Executive Officer

EX-99.1 — PRESS RELEASE, DATED AUGUST 13, 2026

EX-99.1

Filename: ea030178701ex99-1.htm · Sequence: 2

Exhibit

99.1

NeuroOne® Reports

Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%

$2.7 Million in Product

Orders Outpace Shipments of $2.0 Million

Company Has Received

Product Orders for Fiscal Year 2026 of $11.2 Million; Working with Suppliers to Maximize Product Shipments Through End of Fiscal Year

Received ISO 13485

Certification Ahead of Schedule; International Expansion Planned

StereoCED™ Drug

Delivery System Expected to be Available for Research and Investigational Clinical Studies by the End of Fiscal Year 2026

Management to Host

Conference Call at 8:30 a.m. Eastern Time Today

EDEN PRAIRIE, Minn., August 13, 2026 --

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company

dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results and provided

a business update for the third quarter of fiscal year 2026 ended June 30, 2026.

FY Q3 2026 Financial Highlights

● Product revenue increased 16% to $2.0 million,

compared to $1.7 million in the same year-ago period.

● The

Company received $2.7 million of new product orders to ship during the quarter, representing

43% growth in product orders year over year. Product orders exceeded recognized revenue during the quarter

with backlog of $1.7 million as of June 30, 2026.

● The

Company has received product orders of $11.2 million for fiscal year 2026. Recognized revenue

is expected to range from $9.2 million to $10.5 million depending primarily on manufacturing

completion and timing of shipments, with any unshipped orders contributing to backlog. The

Company is working closely with manufacturing partners to maximize shipments.

● Product

gross profit increased 29% to $1.2 million, compared to $0.9 million in the same year-ago

quarter.

● Product

gross margins increased to 59.9%, compared to 53.9% in the same year-ago quarter.

● Subsequent to quarter end, our

lead investor increased ownership of NeuroOne’s outstanding common stock from 7.4% to 12.5%.

Recent

Operational Highlights

● The

Company received ISO 13485:2016 Certification enabling the Company to commercialize across

different countries. Geographies may have additional requirements to gain commercial access,

although this is a major achievement signaling that the Company follows an internationally

recognized quality management system that will provide near term commercial opportunities

to help grow product revenues.

● The

Journal of Neurosurgery published an article by the Mayo Clinic in Jacksonville, Florida

titled, “Stereo-electroencephalography–guided radiofrequency thermocoagulation

in patients with implanted neuromodulation devices: patient series” which evaluated

the use of NeuroOne’s OneRF® Brain Ablation System in patients who have

implanted neuromodulation devices. The article concluded that these procedures may be performed

without interfering with existing hardware as well as providing meaningful seizure reduction.

This expands the pool of treatable patients to include those with existing neuromodulation

implants.

● NeuroOne

expects its StereoCED™ platform to be available by the end of fiscal year 2026 for

animal research and FDA IDE approved studies. In advance of this, the Company released a

breakthrough white paper titled “StereoCED™ - A Scalable Platform for CNS Drug

Delivery” – highlighting how its drug delivery platform leverages robotic stereotactic

systems already established in neurosurgical operating rooms and has the potential to significantly

reduce procedure time while addressing key barriers to the scalable commercial delivery of

brain therapeutics. The white paper comes at a pivotal time, as the first potential blockbuster

intraparenchymal brain-delivered therapy could receive FDA approval as early as 2027.

● Expanded

drug delivery program through collaboration with Mayo Clinic supporting a newly funded research

program by CURE Childhood Cancer to evaluate a novel treatment approach for pediatric diffuse

midline glioma (DMG), one of the most aggressive and difficult-to-treat childhood brain cancers.

The study will utilize NeuroOne’s StereoCED™ drug delivery platform, which combines

precision intracranial drug delivery with a simultaneous neural recording, offering investigators

additional insight into both drug delivery and the effects on the surrounding neural environment.

● Advanced

brain drug delivery platform through collaboration with University of Minnesota to advance

a study evaluating next-generation epilepsy therapies using NeuroOne’s StereoCED™

drug delivery platform. The study is designed to test novel therapeutics delivered locally

into specific brain regions involved in sustaining seizures with the goal of improving clinical

efficacy and lowering systemic toxicity and off-target effects.

● Advanced

discussions underway with a tier-one potential strategic partner to develop and supply the

access tools for our basivertebral nerve ablation system to treat lower back pain.

● The

Company was added to the Russell Microcap Index as part of the semi-annual June 2026 reconstitution

of the Russell US Indexes.

Management

Commentary

“This

quarter marked another period of revenue growth compared to 2025, with product revenue increasing 16% year-over-year to $2.0

million,” said Dave Rosa, CEO of NeuroOne. “Importantly, this growth is improving margins – product gross margins

reached a record 59.9%, driven by a 29% increase in product gross profit to $1.2 million compared to the prior year period. Even more encouraging is that new product

orders of $2.7 million during the quarter meaningfully outpaced revenue recognized during the quarter, growing our backlog to $1.7

million.

“Looking

at the rest of the fiscal year, there’s a lot to be excited about: the launch of our StereoCED™ drug delivery platform for

investigational and animal studies, continued growth of the OneRF® Brain Ablation System, onboarding independent distributor reps

for the OneRF® Trigeminal Nerve Ablation System, selecting a partner for our basivertebral nerve ablation access tools, and planning

for international expansion. In total, we continue to make meaningful progress with our technology platform across all verticals while

adding to the patient success stories for those who are treated with our technology. This is our driving motivation.”

Summary

of NeuroOne Therapies

OneRF®

Trigeminal Nerve Ablation System:

● Scheduling

evaluations at new centers based on interest generated at the American Society for Stereotactic

and Functional Neurosurgery Biennial Meeting this past June.

● Interviewed

distributors to expand commercialization efforts to support a direct regional sales distribution

model.

SteroeCED™

Drug Delivery Program:

● White

paper released discussing potential benefits of the system.

● Preparing

for launch of animal research studies and FDA approved IDE gene and/or cell therapies by

the end of fiscal year 2026.

● Selected

by the Mayo Clinic in Rochester, Minnesota to supply devices for a study to treat a form

of pediatric glioblastomas (brain tumors).

● Selected

by the University of Minnesota to supply devices for a study to treat drug resistant epilepsy.

Basivertebral

Nerve Ablation:

● Regulatory

strategy complete; expected FDA 510(k) pathway.

● In

discussions with potential partner to develop access tools for system.

● Device

optimization for target lesion size in process.

OneRF®

Ablation System in the Brain:

● ISO

13485 certification received in August 2026. This will allow the Company to selectively target

international markets.

● Expect

to enroll first patient by the end of September for the brain ablation post-market registry,

with five centers currently participating.

● The

Journal of Neurosurgery published an article by the Mayo Clinic in Jacksonville, Florida

titled: “Stereo-electroencephalography–guided radiofrequency thermocoagulation

in patients with implanted neuromodulation devices: patient series” which evaluated

the use of NeuroOne’s OneRF® Brain Ablation System in patients who have implanted

neuromodulation devices.

Third

Quarter Fiscal 2026 Financial Results

Product

revenue increased to $2.0 million in the third quarter of fiscal 2026, a 16% increase compared to $1.7 million in the same year-ago quarter.

The increase was primarily driven by higher sales of OneRF® Products.

Product

gross profit increased 29% to $1.2 million, driving a product gross margin expansion to a record 59.9% in the third quarter of fiscal

2026, compared to $0.9 million, or 53.9%, in the same year-ago quarter. This 6.0 percentage point increase reflects a more favorable

sales mix toward higher margin products.

Total

operating expenses were $3.6 million in the third quarter of fiscal 2026, compared to $2.8 million in the same year-ago quarter. Selling,

General & Administrative expenses were $2.2 million, compared to $1.6 million as a result of increased headcount, sales and marketing

costs, professional fees and other operating costs in the same year-ago quarter. Research & Development expenses were $1.4 million,

compared to $1.2 million in the same year-ago quarter, reflecting the timing of product development activities.

Net

loss in the third quarter of fiscal 2026 was $2.0 million, or ($0.23) per basic share and ($0.28) per diluted share, compared to net

loss of $1.5 million, or ($0.19) per basic share and ($0.19) per diluted share, in the prior-year quarter.

of June 30, 2026, cash and cash equivalents totaled $2.0 million, compared to $6.6 million as of September 30, 2025. Accounts receivable

were $1.1 million as of June 30, 2026, compared to $1.3 million as of September 30, 2025, and inventory, net was $2.3 million as of June

30, 2026, compared to $2.2 million as of September 30, 2025. During the third quarter of fiscal 2026, the Company raised $0.4 million

through its at-the-market offering program. Through June 30, 2026, the Company raised gross proceeds of $8.4 million under the at-the-market (“ATM”) program.

Subsequent to quarter-end, on July 13, 2026, the Company raised another $1.0 million through the issuance of 400,346 shares under the

ATM program representing the second time in calendar 2026 the ATM was utilized.

The

Company had working capital of $3.7 million as of June 30, 2026, compared to working capital of $7.9 million as of September 30, 2025.

The Company had no debt outstanding as of June 30, 2026.

All

share and per share amounts in this release have been retroactively adjusted to reflect the one-for-six reverse stock split of the Company’s

issued and outstanding common stock, which began trading on a split-adjusted basis on The Nasdaq Capital Market on April 16, 2026.

Conference

Call and Webcast

Management

will host an investor conference call and webcast today, Thursday, August 13, 2026, at 8:30 a.m. Eastern time to discuss the Company’s

fiscal third quarter 2026 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate,

please use the following information:

Date:

Thursday, August 13, 2026

Time:

8:30 a.m. Eastern time

U.S.

Dial-In (Toll Free): 888-506-0062

International

Dial-In: 973-528-0011

Participant

Access Code: 549778

Webcast:

NMTC FY Q3 2026 Earnings Call Webcast

Please

join at least five minutes before the start of the call to ensure timely participation.

playback of the call will be available through Thursday, August 27, 2026. To listen to the replay, please call 877-481-4010 within the

United States or 919-882-2331 when calling internationally, using replay passcode 54304. A webcast replay will also be available using

the webcast link above through August 13, 2027.

About

NeuroOne

Medical Technologies Corporation (NASDAQ: NMTC) is a medical technology company focused on improving surgical care options and outcomes

for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode

technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation

System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations

and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged

in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information,

please visit nmtc1.com.

Forward

Looking Statements

This

press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,

and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information

contained in this press release may be a forward looking statement that reflects NeuroOne’s current views about future events

and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity,

performance or achievements to be materially different from the information expressed or implied by these forward-looking

statements. In some cases, you can identify forward looking statements by the words or phrases “may,”

“might,” “will,” “could,” “would,” “should,” “expect,”

“intend,” “plan,” “forecasts,” “objective,” “anticipate,”

“believe,” “estimate,” “predict,” “project,” “potential,”

“target,” “seek,” “contemplate,” “continue, “focused on,” “committed

to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements

about the future. Forward looking statements may include statements regarding the potential sales of the StereoCEDTM drug

delivery platform in investigational clinical studies or animals in Q4 fiscal 2026, 2026 guidance, the collaborations with the

University of Minnesota and other companies, our ability to expand internationally, our ability to ship back-ordered product, our

ability to expand the sales of our OneRF® Trigeminal Nerve Ablation System, our and the Company’s ability to expand

revenue. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these

statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we

cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our

control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing

requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology

whether due to supply chain disruptions, labor shortages or otherwise risks that our technology will not perform as expected based

on results of our pre-clinical and clinical trials risks related to uncertainties associated with the Company’s capital

requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or

retain coverage or adequate reimbursement for our technology uncertainties inherent in the development process of our technology

risks related to changes in regulatory requirements or decisions of regulatory authorities that we may not have accurately estimated

the size and growth potential of the markets for our technology risks related to clinical trial patient enrollment and the results

of clinical trials that we may be unable to protect our intellectual property rights and other risks, uncertainties and assumptions,

including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission.

These forward looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or

update any forward looking statements for any reason, even if new information becomes available in the future.

Caution:

Federal law restricts this device to sale by or on the order of a physician.

* Disclaimer:

This recounts several patients’ experiences and may not be representative of all patient outcomes.

Contact

Group – MZ North America

NMTC@mzgroup.us

NeuroOne

Medical Technologies Corporation

Condensed

Balance Sheets

June

30,

September

30,

2026

2025

(Unaudited)

Assets

Current

assets:

Cash

and cash equivalents

$ 2,047,596

$ 6,570,382

Accounts

receivable

1,098,965

1,264,805

Inventory,

net

2,290,254

2,226,805

Deferred

offering costs

33,046

22,920

Prepaid

expenses

318,940

141,372

Total

current assets

5,788,801

10,226,284

Intangible

assets, net

28,210

44,946

Right-of-use

asset

166,751

255,195

Property

and equipment, net

202,333

259,222

Total

assets

$ 6,186,095

$ 10,785,647

Liabilities

and Stockholders’ Equity

Current

liabilities:

Accounts

payable

$ 905,716

$ 1,010,369

Accrued

expenses and other liabilities

1,135,711

1,292,714

Total

current liabilities

2,041,427

2,303,083

Warrant

liability

303,805

1,266,894

Operating

lease liability, long term

73,320

143,148

Total

liabilities

2,418,552

3,713,125

Commitments

and contingencies (Note 4)

Stockholders’

equity:

Preferred

stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding.

—

Common

stock, $0.001 par value; 100,000,000 shares authorized; 8,702,982 and 8,334,336 shares issued and outstanding as of June 30, 2026

and September 30, 2025, respectively.

8,703

8,334

Additional

paid–in capital

88,194,870

85,673,975

Accumulated

deficit

(84,436,030 )

(78,609,787 )

Total

stockholders’ equity

3,767,543

7,072,522

Total

liabilities and stockholders’ equity

$ 6,186,095

$ 10,785,647

NeuroOne

Medical Technologies Corporation

Condensed

Statements of Operations

(unaudited)

For

the

Three Months Ended

June 30,

For

the

Nine Months Ended

June 30,

2026

2025

2026

2025

Product

revenue

$ 1,973,105

$ 1,696,050

$ 6,727,790

$ 6,356,767

Cost

of product revenue

790,496

781,215

2,987,089

2,743,982

Product

gross profit

1,182,609

914,835

3,740,701

3,612,785

License

revenue

—

3,000,000

Operating

expenses:

Selling,

general and administrative

2,181,768

1,618,950

5,986,594

5,602,818

Research

and development

1,425,153

1,182,485

4,282,923

3,865,376

Total

operating expenses

3,606,921

2,801,435

10,269,517

9,468,194

Loss

from operations

(2,424,312 )

(1,886,600 )

(6,528,816 )

(2,855,409 )

Fair

value change in warrant liability

405,702

319,625

620,171

1,099,421

Financing

costs

—

(9,325 )

—

(334,063 )

Other

income

12,279

75,432

82,402

103,898

Loss

before income taxes

(2,006,331 )

(1,500,868 )

(5,826,243 )

(1,986,153 )

Provision

for income taxes

—

Net

loss

$ (2,006,331 )

$ (1,500,868 )

$ (5,826,243 )

$ (1,986,153 )

Net

loss per share (Note 3):

Basic

$ (0.23 )

$ (0.19 )

$ (0.68 )

$ (0.32 )

Diluted

$ (0.28 )

$ (0.19 )

$ (0.75 )

$ (0.32 )

Number

of shares used in per share calculations (Note 3):

Basic

8,661,624

8,100,603

8,511,313

6,141,509

Diluted

8,739,505

8,100,603

8,621,075

6,141,509

GRAPHIC

Filename: ea030178701_ex99-1img1.jpg · Sequence: 3

Binary file (7945 bytes)

Download ea030178701_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 13, 2026

Entity File Number

001-40439

Entity Registrant Name

NeuroOne

Medical Technologies Corporation

Entity Central Index Key

0001500198

Entity Tax Identification Number

27-0863354

Entity Incorporation, State or Country Code

Entity Address, Address Line One

7599

Anagram Dr.

Entity Address, City or Town

Eden Prairie

Entity Address, State or Province

Entity Address, Postal Zip Code

55344

City Area Code

952

Local Phone Number

426-1383

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value

$0.001 per share

Trading Symbol

NMTC

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration